GS9674



NAME OF DRUG : GS9674

ALSO KNOWN AS : GS9674

LABORATORY : GILEAD

STATUS AND ADVANCEMENT

Type of drug : FXR agonist

Clinical trials advancement : Ongoing Phase 2b

Estimated time to market : 88 months.

LABORATORY ABSTRACT ON THE DRUG

GS-9674 is a selective, non-steroidal agonist of the Farnesoid X receptor (FXR), a nuclear hormone receptor that is highly expressed in the gastrointestinal tract and liver. FXR is the primary regulator of bile acid synthesis and plays important roles in glucose and lipid metabolism. Results from two preclinical studies selected for oral presentation highlight the therapeutic efficacy of GS-9674 in animal models of NASH. In a Gilead-led study, a diet-induced obesity model demonstrated that mice administered GS-9674 had reduced hepatic steatosis and fibrosis, as well as serum levels of cholesterol, ALT and AST compared with untreated animals (Oral PS-066). In a second study, presented by Philipp Schwabl, MD, and led by Michael Trauner, MD, both of the Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, rats were administered sodium nitrate and fed a choline-deficient, high-fat diet for 10 weeks that resulted in cirrhosis and portal hypertension. Data demonstrate that GS-9674 treatment had dose-dependent anti-fibrotic effects and lowered portal pressure (Oral PS-058). 

RECENT NEWS ON GS9674

2017-01-05 : Phenex Pharmaceuticals AG Receives $100M Milestone Payment From Gilead (GILD)

SOME PUBLICATIONS RELATED WITH GS9674

December 2017 : Targeting bile acids and lipotoxicity for NASH treatment

April 2017 : Pharmacokinetics of selonsertib, GS-9674, and/or GS-0976 in combination in healthy subjects

January 2017 : Mice species-specific control of hepatocarcinogenesis and metabolism by FGF19/FGF15 (necessity to monitor HCC risk with FXR agonists )

February 2013 : Dual actions of fibroblast growth factor 19 on lipid metabolism

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH GS9674


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE